Lung Function in Patients with Trophoblastic Disease Treated with Methotrexate
Author Information
Author(s): AM Gillespie, PC Lorigan, CR Radstone, JC Waterhouse, RE Coleman, BW Hancock
Primary Institution: Sheffield Supraregional Trophoblastic Disease Screening and Treatment Centre
Hypothesis
What is the effect of low-dose methotrexate on pulmonary function in patients with trophoblastic disease?
Conclusion
Low-dose methotrexate is effective for treating trophoblastic disease but may cause temporary pulmonary toxicity.
Supporting Evidence
- 85% of patients achieved remission with methotrexate treatment.
- 20% of patients experienced pleuritic chest pain and dyspnoea.
- Significant reduction in TLCO from 8.15 to 7.38 mmol min-' kPa-1 after treatment.
Takeaway
This study looked at how a medicine called methotrexate affects the lungs of patients with a specific type of disease. It found that while the medicine works well, it can also cause some lung problems.
Methodology
Pulmonary function tests were performed before and after treatment in 16 patients receiving methotrexate.
Limitations
The study had a small sample size and did not perform bronchoalveolar lavage or lung biopsy.
Participant Demographics
Median age of participants was 25.5 years, with a range of 15-35 years.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Want to read the original?
Access the complete publication on the publisher's website